Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Novo’s Business Plan For Tresiba Insulin Includes ‘Moderate’ Price Premium

Executive Summary

Reduced risk of hypoglycemia compared to competing long-acting insulin is not in Tresiba’s FDA label, at least not yet, but Novo Nordisk sees room for differentiation in duration and dosing flexibility.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register